Glyriva50 mcg

Glyriva is a synthetic anticholinergic (antimuscarinic) agent used in several distinct clinical settings depending on its formulation.

Established/FDA-approved uses

• Injectable form: Given before anesthesia to reduce salivary, tracheobronchial, and pharyngeal secretions and to reduce the risk of aspiration (antisialogogue); given during surgery to block cardiac vagal reflexes (e.g., preventing bradycardia caused by vagal stimulation or certain anesthetic agents); given intravenously together with neostigmine or another anticholinesterase to counteract the muscarinic side effects (bradycardia, excessive secretions) that occur when reversing non-depolarizing neuromuscular blockade at the end of surgery.
• Oral form: Approved for chronic, severe drooling (sialorrhea) associated with neurologic conditions (e.g., cerebral palsy) in children 3 years and older.
• Inhaled form (as glycopyrrolate/glycopyrronium inhalation powder): Long-term, once- or twice-daily maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. It is a maintenance bronchodilator and is not indicated for relief of acute bronchospasm.

Adjunctive/older uses

• Historically used orally as adjunctive therapy (with other measures) for peptic ulcer disease, to reduce gastric acid secretion; this use has largely been superseded by newer acid-suppressing agents.

The exact indication and approved use depend on the specific formulation (injection, oral, or inhaled) — see Dosage and Administration for formulation-specific details.

Each formulation of Glycopyrronium Bromide contains Glycopyrronium Bromide as the sole active pharmaceutical ingredient, though the exact strength varies by product:

• Injection: Glycopyrronium Bromide solution for intravenous or intramuscular use (commonly 0.2 mg/mL).
• Oral: Glycopyrronium Bromide tablets or oral solution.
• Inhalation: Glycopyrronium Bromide as a dry powder for oral inhalation via a specific inhaler device.

Inactive ingredients vary by manufacturer and formulation; consult the specific product label for details.

Glyriva is a synthetic quaternary ammonium anticholinergic (antimuscarinic) compound. Because it is a quaternary ammonium salt, it does not readily cross the blood-brain barrier or placenta compared with tertiary amine anticholinergics such as atropine, which generally results in fewer central nervous system effects at usual doses.

Glyriva is formulated as an injection (used perioperatively in anesthesia), an oral solution/tablet (used for chronic drooling and, historically, peptic ulcer disease), and an inhalation powder (used as a long-acting bronchodilator in COPD).

Glyriva belongs to the following therapeutic classes:

• Anticholinergic / Antimuscarinic agent
• Antisialogogue (secretion-reducing agent) — injectable form
• Antispasmodic — oral form (historical GI use)
• Long-Acting Muscarinic Antagonist (LAMA) / bronchodilator — inhaled form, used in COPD management

Glycopyrronium Bromide competitively and reversibly blocks the action of acetylcholine at muscarinic (M1–M3) receptors on smooth muscle, cardiac muscle, and exocrine glands.

• Secretions: Blocks M3 receptors on salivary, bronchial, and gastric glands, reducing salivary, respiratory tract, and gastric acid secretions.
• Heart rate: Blocks vagally-mediated M2 receptors in the SA node, which can increase heart rate and counteract vagally-induced bradycardia.
• Smooth muscle: Relaxes smooth muscle in the gastrointestinal and respiratory tracts (bronchodilation), and in the urinary tract.
• Eye: Can cause mydriasis (pupil dilation) and cycloplegia at higher systemic exposure.

Onset and duration vary by route: intravenous administration produces effects within 1 minute (vagal blockade) to 2–3 minutes (antisialogogue effect), with a duration of roughly 2–7 hours depending on the effect measured. Inhaled Glycopyrronium Bromide acts locally in the lungs to provide sustained bronchodilation over 12–24 hours, supporting once- or twice-daily dosing.

Glyriva injection may be given intravenously (slowly) or intramuscularly, as directed by the treating physician or anesthesiologist; it should not be mixed in the same syringe with drugs of unconfirmed compatibility.

Oral Glyriva (tablet or solution) is usually taken on an empty stomach, about 1 hour before or 2 hours after meals, unless otherwise directed, since food can affect absorption.

Inhaled Glyriva is administered only via its specific inhaler device; capsules intended for inhalation must never be swallowed. Patients should be trained in correct inhaler technique by a healthcare provider or pharmacist.

Do not change the dose, frequency, or route of administration of Glyriva without consulting the prescribing physician.

Glyriva has the following clinically significant drug interactions:

• Other anticholinergic/antimuscarinic drugs (e.g., antihistamines, tricyclic antidepressants, phenothiazines, other antispasmodics): concurrent use with Glyriva can produce additive anticholinergic effects (dry mouth, blurred vision, urinary retention, constipation, confusion).
• Potassium chloride (solid oral dosage forms): anticholinergic-induced slowing of gastrointestinal transit with Glyriva may increase the risk of solid potassium chloride causing GI mucosal lesions.
• Digoxin (slow-dissolution oral tablets): Glyriva can delay gastric emptying and increase the bioavailability of certain digoxin formulations, potentially raising digoxin levels.
• Antacids: may reduce absorption of oral Glyriva; oral doses should be separated in time from antacid administration.
• Haloperidol/other antipsychotics: co-administration with Glyriva has been associated with decreased antipsychotic plasma levels or worsening of psychiatric symptoms in some reports; monitor clinically.
• Other long-acting muscarinic antagonists or anticholinergic bronchodilators (for inhaled Glyriva): co-administration with another LAMA is not recommended due to additive anticholinergic effects.

Adverse effects of Glyriva are mainly related to its anticholinergic action and are generally dose-related.

Common

• Dry mouth
• Constipation
• Blurred vision, mydriasis (pupil dilation), photophobia
• Urinary hesitancy or retention
• Decreased sweating
• Tachycardia, palpitations
• Headache, dizziness, drowsiness (especially with inhaled/oral forms)

Less common/serious

• Heat prostration (fever, heat stroke) due to reduced sweating, particularly in hot environments
• Nervousness, insomnia, or confusion (more likely in elderly patients)
• Allergic reactions, including skin rash
• Paradoxical bronchospasm (rare, with inhaled form) — discontinue and seek medical attention if this occurs
• Cardiac arrhythmias in susceptible patients

Adequate and well-controlled studies of Glyriva in pregnant women are limited. Glyriva should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use in pregnancy.

It is not known whether Glyriva is excreted in human breast milk. Because anticholinergic agents can suppress lactation and many drugs are excreted in breast milk, caution is advised when Glyriva is administered to a breastfeeding woman; a physician should weigh the benefits of treatment against potential risk to the infant.

Glyriva should be used with caution in the following situations (see Contraindications for absolute contraindications):

• Hot or humid environments: Glyriva reduces sweating and can predispose to heat prostration/heat stroke, especially in children and in warm climates.
• Cardiac disease: use with caution in patients with tachyarrhythmias, coronary artery disease, congestive heart failure, or hypertension, as Glyriva can increase heart rate.
• Autonomic neuropathy, hyperthyroidism, or renal disease: use with caution and appropriate monitoring.
• Elderly patients: more susceptible to anticholinergic adverse effects (confusion, urinary retention, constipation, heat intolerance); use the lowest effective dose.
• Ulcerative colitis: large doses may suppress intestinal motility and precipitate or worsen toxic megacolon; use with caution.
• Hiatal hernia with reflux esophagitis: anticholinergics may aggravate this condition by delaying gastric emptying.

Patients should be counseled to avoid activities requiring mental alertness (e.g., driving) until they know how Glyriva affects them, since blurred vision or drowsiness can occur.

Overdose of Glyriva may cause an exaggeration of its anticholinergic effects, including dry mouth, blurred vision, dilated pupils, flushed/hot dry skin, difficulty swallowing, marked tachycardia, urinary retention, agitation or restlessness, and, in severe cases, cardiovascular collapse, curare-like effects (muscle weakness leading to respiratory difficulty), or hyperthermia.

Suspected overdose of Glyriva is a medical emergency. Seek immediate medical attention or contact emergency services/poison control immediately. Do not attempt to manage a suspected overdose at home; treatment must be provided under direct medical supervision, as it may involve specific antidotal and supportive care measures.

Store Glyriva at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the packaging. Discard any unused injectable solution as directed by the pharmacist once the vial has been opened, according to the specific product's instructions.

Pediatric use: Oral Glyriva is approved for chronic sialorrhea in children 3 years of age and older with neurologic conditions; dosing must be individualized and titrated by a physician. The injectable form is used in pediatric anesthesia based on weight, under specialist supervision; safety and efficacy of some formulations have not been established in neonates. The inhaled form is not indicated for use in children.

Elderly: Elderly patients are more sensitive to the anticholinergic effects of Glyriva (confusion, constipation, urinary retention, heat intolerance); start with the lowest effective dose and monitor closely.

Renal impairment: Since Glyriva is primarily renally eliminated, dose reduction or an increased dosing interval may be needed in moderate-to-severe renal impairment; monitor for increased anticholinergic effects.

Hepatic impairment: Limited data are available; use Glyriva with caution.

Pregnancy and lactation: See Pregnancy and Lactation section.

The duration of treatment with Glyriva depends on the indication:

• Perioperative (injectable) use: Single or intermittent doses during the immediate preoperative/intraoperative period; not intended for ongoing long-term use.
• Chronic sialorrhea (oral): Long-term use as directed by the physician, with periodic reassessment of benefit versus anticholinergic side effects.
• COPD maintenance (inhaled): Long-term, ongoing daily use for as long as the physician determines it is needed to control symptoms; it is not intended for as-needed relief of acute symptoms.

• Anticholinergics
• Antimuscarinics
• Antispasmodics
• Long-Acting Muscarinic Antagonists (LAMA)

Glycopyrronium Bromide is a competitive antagonist at muscarinic acetylcholine receptors (M1, M2, M3). By blocking acetylcholine at these receptor sites, Glycopyrronium Bromide reduces secretions from salivary, bronchial, and gastric glands, blocks vagally-mediated cardiac slowing (increasing heart rate), relaxes smooth muscle in the gastrointestinal and respiratory tracts, and reduces sweat gland activity. As a quaternary ammonium compound, it has limited penetration into the central nervous system compared with tertiary amine anticholinergics.

B

Oral Glyriva solution is approved for the treatment of chronic, severe drooling (sialorrhea) associated with neurologic conditions (such as cerebral palsy) in children 3 to 16 years of age; the dose is individualized based on body weight and titrated by the treating physician to the lowest effective dose.

Injectable Glyriva is used in pediatric anesthesia (as an antisialogogue and to prevent vagally-mediated bradycardia) at weight-based doses under the direct supervision of an anesthesiologist; safety and efficacy have not been specifically established in neonates.

The inhaled formulation of Glyriva for COPD is indicated only for adults; safety and efficacy in children have not been established, and it should not be used in the pediatric population for this indication.